CN117265051A - Sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide and preparation method and application thereof - Google Patents
Sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide and preparation method and application thereof Download PDFInfo
- Publication number
- CN117265051A CN117265051A CN202311192951.9A CN202311192951A CN117265051A CN 117265051 A CN117265051 A CN 117265051A CN 202311192951 A CN202311192951 A CN 202311192951A CN 117265051 A CN117265051 A CN 117265051A
- Authority
- CN
- China
- Prior art keywords
- sea buckthorn
- inhibitory peptide
- glucosidase inhibitory
- alpha
- based high
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000003145 Hippophae rhamnoides Nutrition 0.000 title claims abstract description 88
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 85
- 102100024295 Maltase-glucoamylase Human genes 0.000 title claims abstract description 77
- 108010028144 alpha-Glucosidases Proteins 0.000 title claims abstract description 77
- 230000000694 effects Effects 0.000 title claims abstract description 63
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 240000000950 Hippophae rhamnoides Species 0.000 title description 7
- 241000229143 Hippophae Species 0.000 claims abstract description 82
- 239000007788 liquid Substances 0.000 claims abstract description 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 40
- 229920001184 polypeptide Polymers 0.000 claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 229920001661 Chitosan Polymers 0.000 claims abstract description 21
- 239000012752 auxiliary agent Substances 0.000 claims abstract description 14
- 239000000243 solution Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 108091005658 Basic proteases Proteins 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000002244 precipitate Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 11
- 239000000758 substrate Substances 0.000 claims description 11
- 201000001421 hyperglycemia Diseases 0.000 claims description 10
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 9
- 235000019419 proteases Nutrition 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- -1 amine sulfate Chemical class 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 8
- 229910021641 deionized water Inorganic materials 0.000 claims description 8
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 6
- 230000008014 freezing Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000012670 alkaline solution Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 108090000526 Papain Proteins 0.000 claims description 3
- 229940055729 papain Drugs 0.000 claims description 3
- 235000019834 papain Nutrition 0.000 claims description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 238000000605 extraction Methods 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 3
- 230000006872 improvement Effects 0.000 abstract description 3
- 238000000751 protein extraction Methods 0.000 abstract description 3
- 238000004064 recycling Methods 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 23
- 230000005764 inhibitory process Effects 0.000 description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 6
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 238000007696 Kjeldahl method Methods 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000004001 inositols Chemical class 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000008216 xylosides Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Botany (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
The invention discloses a sea-buckthorn-based high-activity alpha-glucosidase inhibitory peptide, a preparation method and application thereof, wherein the sea-buckthorn-based high-activity alpha-glucosidase inhibitory peptide is prepared by optimizing an extraction scheme of sea-buckthorn protein to obviously improve the protein extraction rate, optimizing an enzymolysis system, introducing chitosan as an enzymolysis auxiliary agent to promote enzymolysis, improving the enzyme activity and stability, and simultaneously improving the solubility of sea-buckthorn protein, so that the obvious improvement of the alpha-glucosidase inhibitory effect of polypeptide liquid is realized under the combined action, and the sea-buckthorn-based high-activity alpha-glucosidase inhibitory peptide has important significance for recycling sea-buckthorn.
Description
Technical Field
The invention belongs to the technical field of preparation of active peptides, and particularly relates to a sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, and a preparation method and application thereof.
Background
Sea buckthorn (Hippophae rhamnoides L.) is an important plant for both medicine and food, and has a tap-like inflorescence, orange fruit, sweet and sour taste, and various medical and edible values. The sea buckthorn fruits are rich in nutrition, wherein the vitamin C, E is quite prominent, and meanwhile, the sea buckthorn seed meal and the leaves also have higher nutritional value. Among them, sea buckthorn leaves are attracting attention due to their relatively high protein content and various nutritional components such as essential amino acids and minerals.
The total chemical components extracted from sea buckthorn leaves are 95, wherein 28 flavonoid compounds, 40 phenolic and organic acid compounds, 24 terpene and steroid compounds, 2 inositol compounds and 1 alkaloid compound are included. The protein content in the sea buckthorn leaves can reach 10% -25%, wherein the content of the necessary amino acids such as asparagine, lysine, tryptophan and the like is higher. Similarly, the leaves of Hippophae rhamnoides also contain nutrients such as various flavonoids, polyphenols, vitamins and minerals. It has good biological activities such as antioxidation, anti-inflammatory, antibacterial, blood pressure reduction, blood sugar reduction, etc.
In general, sea buckthorn has various nutritional characteristics and utility values as a nutrient-rich part of sea buckthorn plants. It has rich protein component and high nutritive value, and can be used in food, medicine and cosmetics fields. Meanwhile, the part also contains rich nutrients and bioactive substances, is beneficial to maintaining human health and promoting growth and development, and is a valuable natural resource.
Alpha-glucosidase is an enzyme involved in carbohydrate metabolism that breaks down starchy and other carbohydrates in the body, converting them into glucose for energy. If the alpha-glucosidase activity in the human body is too high, the production and release of glucose in the blood will be accelerated, resulting in an increased risk of hyperglycemia. Therefore, inhibition of α -glucosidase activity has become one of the effective methods for preventing hyperglycemia. Hyperglycemia is a common metabolic disease with an increasing incidence worldwide from year to year. Hyperglycemia may cause various complications such as microangiopathy, neuropathy, cardiovascular disease, etc., in addition to its own harm, and in severe cases may even lead to blindness, amputation, and death. The pathogenesis of hyperglycemia is complex. In the case of insufficient insulin levels, glucose cannot enter the cells for normal metabolism, resulting in an increase in blood glucose. In addition, inflammatory factors produced by adipose tissue and external factors such as diet affect glucose metabolism, and further aggravate the development of hyperglycemia.
Currently, there are many natural hormonal, plant and microbial sources of compounds that have proven useful as alpha-glucosidase inhibitors, such as myrtanin, resveratrol, catechins, xylosides, and the like. These inhibitors affect α -glucosidase activity through different mechanisms, promoting glucose clearance and utilization, thereby lowering blood glucose levels, and improving insulin sensitivity. Experimental and clinical studies lead to the conclusion: the ingestion of these natural inhibitors in an appropriate amount can help prevent the occurrence of metabolic diseases such as hyperglycemia and diabetes. In summary, the regulation of α -glucosidase activity plays an important role in maintaining the energy metabolic balance and preventing metabolic disorders in the human body. The activity of alpha-glucosidase can be regulated and controlled by reasonably using natural inhibitors, and the glucose conversion speed is slowed down, so that the risk of hyperglycemia is reduced.
At present, the research on the preparation of sea buckthorn protein and the technology thereof is very limited, and the research uses sea buckthorn leaves as raw materials for the first time to prepare alpha-glucosidase inhibitory peptide, thereby providing a new direction for the resource utilization of sea buckthorn.
Disclosure of Invention
This section is intended to outline some aspects of embodiments of the invention and to briefly introduce some preferred embodiments. Some simplifications or omissions may be made in this section as well as in the description summary and in the title of the application, to avoid obscuring the purpose of this section, the description summary and the title of the invention, which should not be used to limit the scope of the invention.
The present invention has been made in view of the above and/or problems occurring in the prior art.
Therefore, the invention aims to overcome the defects in the prior art and provide a preparation method of the high-activity alpha-glucosidase inhibitory peptide based on sea buckthorn.
In order to solve the technical problems, the invention provides the following technical scheme: comprising the steps of (a) a step of,
dissolving sea buckthorn powder into alkaline solution to reach pH of 10-12, heating and stirring, centrifuging and maintaining supernatant;
adding an acidic regulator into the supernatant to enable the pH value of the solution to be 4-5, standing, precipitating, centrifuging to obtain a precipitate, and freeze-drying the precipitate to obtain the sea buckthorn protein;
dissolving sea buckthorn protein in deionized water, adding protease and enzymolysis auxiliary agent, heating and stirring for enzymolysis, centrifuging after enzymolysis is completed to obtain polypeptide liquid containing high-activity alpha-glucosidase inhibitory peptide, concentrating the polypeptide liquid, freezing and drying to obtain the high-activity alpha-glucosidase inhibitory peptide.
As a preferable scheme of the preparation method of the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, the invention comprises the following steps: the alkaline solution comprises one of sodium hydroxide solution, potassium hydroxide solution or sodium bicarbonate solution.
As a preferable scheme of the preparation method of the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, the invention comprises the following steps: the acidity regulator comprises one of hydrochloric acid, sulfuric acid or acetic acid.
As a preferable scheme of the preparation method of the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, the invention comprises the following steps: the feed liquid ratio of the sea buckthorn protein to the deionized water is 1:20-50.
As a preferable scheme of the preparation method of the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, the invention comprises the following steps: the protease comprises one or more of alkaline protease, papain or pepsin.
As a preferable scheme of the preparation method of the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, the invention comprises the following steps: the addition amount of the protease is 0.1% -1% of the substrate sea buckthorn protein.
As a preferable scheme of the preparation method of the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, the invention comprises the following steps: the enzymolysis auxiliary agent comprises one or more of chitosan, polyethylene glycol, amine sulfate or ethylene glycol.
As a preferable scheme of the preparation method of the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, the invention comprises the following steps: the addition amount of the enzymolysis auxiliary agent is 1-5% of the substrate sea buckthorn protein.
As a preferable scheme of the preparation method of the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide, the invention comprises the following steps: the enzymolysis time is 2-6 h.
It is a further object of the present invention to provide the use of a sea buckthorn-based highly active α -glucosidase inhibitory peptide for the preparation of a product for the treatment or prevention of hyperglycemia.
The invention has the beneficial effects that:
the invention provides a method for preparing alpha-glucosidase inhibitory peptide from sea buckthorn, which comprises the steps of firstly optimizing an extraction scheme of sea buckthorn protein, obviously improving the protein extraction rate, secondly optimizing an enzymolysis system, introducing chitosan as an enzymolysis auxiliary agent to promote enzymolysis, improving the enzyme activity and stability, simultaneously improving the solubility of sea buckthorn protein, realizing the obvious improvement of the alpha-glucosidase inhibitory effect of polypeptide liquid under the combined action, and having important significance for recycling sea buckthorn.
Detailed Description
In order that the above-recited objects, features and advantages of the present invention will become more apparent, a more particular description of the invention will be rendered by reference to specific embodiments thereof which are illustrated in the appended drawings.
In the following description, numerous specific details are set forth in order to provide a thorough understanding of the present invention, but the present invention may be practiced in other ways other than those described herein, and persons skilled in the art will readily appreciate that the present invention is not limited to the specific embodiments disclosed below.
Further, reference herein to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic can be included in at least one implementation of the invention. The appearances of the phrase "in one embodiment" in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments.
The protein content in the invention is measured by a Kjeldahl method.
The method for detecting the inhibition rate of the alpha-glucosidase activity comprises the following steps:
preparing an alpha-glucosidase solution with a concentration of 1U/mL and a pNPG solution with a concentration of 2.5mmo/L by adopting PBS (pH=6.8);
400. Mu.L of the LPBS solution, 400. Mu.L of the alpha-glucosidase solution and 400. Mu.L of the differently treated samples were added to a 10mL tube, mixed well and incubated at 37℃for 15min. Then 200uLpNPG solution is added, mixed evenly, the incubation condition is the same as the previous step, and finally 1500 mu L of 0.2mol/LNa is added 2 CO 3 The reaction was terminated, acarbose was used as a positive control, and the inhibition of α -glucosidase was calculated by measuring at 405nm using an enzyme-labeled instrument.
The raw materials used in the invention are all commonly and commercially available in the field without special description.
Example 1
The embodiment provides a preparation method of a high-activity alpha-glucosidase inhibitory peptide, which specifically comprises the following steps:
1) Dissolving Hippophae rhamnoides powder in sodium hydroxide solution according to water ratio of 30:1 to make pH of the solution be 11, heating and stirring at 40deg.C for 90min, centrifuging at 4000rpm for 20min, and retaining supernatant;
2) Adding acetic acid as an acidic regulator into the supernatant to enable the pH of the solution to be 4.5, standing and precipitating for 60min, centrifuging at 4000rpm for 20min to obtain a precipitate, and freeze-drying the precipitate at-23 ℃ for 72h to obtain sea buckthorn protein, wherein the protein content in the sea buckthorn protein is measured to be 56.8%;
3) Dissolving sea buckthorn protein in deionized water according to a feed liquid ratio of 1:35, adding alkaline protease with substrate sea buckthorn protein content of 0.5% and chitosan with substrate sea buckthorn protein content of 2.5%, heating and stirring at 50 ℃ for enzymolysis for 4 hours, centrifuging at 4000rpm for 20min after enzymolysis is finished to obtain polypeptide liquid containing high-activity alpha-glucosidase inhibitory peptide, and detecting the inhibitory effect of the polypeptide liquid on alpha-glucosidase;
4) Concentrating, freezing and drying the polypeptide liquid to obtain the high-activity alpha-glucosidase inhibitory peptide.
The inhibition rate of alpha-glucosidase in the polypeptide liquid obtained in the step 3) of this example was found to be 97.8%.
Example 2
The difference between this example and example 1 is that the protease type and the enzymatic hydrolysis auxiliary type in the enzymatic hydrolysis process are adjusted, specifically:
1) Dissolving Hippophae rhamnoides powder in sodium hydroxide solution according to water ratio of 30:1 to make pH of the solution be 11, heating and stirring at 40deg.C for 90min, centrifuging at 4000rpm for 20min, and retaining supernatant;
2) Adding acetic acid as an acidic regulator into the supernatant to enable the pH of the solution to be 4.5, standing and precipitating for 60min, centrifuging at 4000rpm for 20min to obtain a precipitate, and freeze-drying the precipitate at-23 ℃ for 72h to obtain sea buckthorn protein, wherein the protein content in the sea buckthorn protein is measured to be 56.8%;
3) Dissolving sea buckthorn protein in deionized water according to a feed liquid ratio of 1:35, adding pepsin with a substrate sea buckthorn protein content of 0.5% and amine sulfate with a substrate sea buckthorn protein content of 1.5%, heating and stirring at a temperature of 50 ℃ for enzymolysis for 4 hours, centrifuging at 4000rpm for 20 minutes after enzymolysis is finished to obtain polypeptide liquid containing high-activity alpha-glucosidase inhibitory peptide, and detecting the inhibitory effect of the polypeptide liquid on alpha-glucosidase;
4) Concentrating, freezing and drying the polypeptide liquid to obtain the high-activity alpha-glucosidase inhibitory peptide.
The inhibition rate of alpha-glucosidase in the polypeptide liquid obtained in the step 3) of the present example was measured to be 94.5%.
Comparative example 1
The comparative example differs from example 1 in that no enzymolysis auxiliary agent is added, specifically:
1) Dissolving Hippophae rhamnoides powder in sodium hydroxide solution according to water ratio of 30:1 to make pH of the solution be 11, heating and stirring at 40deg.C for 90min, centrifuging at 4000rpm for 20min, and retaining supernatant;
2) Adding acetic acid as an acidic regulator into the supernatant to enable the pH of the solution to be 4.5, standing and precipitating for 60min, centrifuging at 4000rpm for 20min to obtain a precipitate, and freeze-drying the precipitate at-23 ℃ for 72h to obtain sea buckthorn protein, wherein the protein content in the sea buckthorn protein is measured to be 56.8%;
3) Dissolving sea buckthorn protein in deionized water according to a feed liquid ratio of 1:35, adding alkaline protease with substrate sea buckthorn protein content of 0.5%, heating and stirring at 50 ℃ for enzymolysis for 4 hours, centrifuging at 4000rpm for 20 minutes after enzymolysis is finished to obtain polypeptide liquid containing high-activity alpha-glucosidase inhibitory peptide, and detecting the inhibitory effect of the polypeptide liquid on alpha-glucosidase;
4) Concentrating, freezing and drying the polypeptide liquid to obtain the high-activity alpha-glucosidase inhibitory peptide.
The inhibition rate of alpha-glucosidase in the polypeptide liquid obtained in the step 3) of the present example was measured to be 90.8%.
Comparative example 2
This comparative example differs from example 1 in that the acidity regulator is adjusted to hydrochloric acid, specifically:
1) Dissolving Hippophae rhamnoides powder in sodium hydroxide solution according to water ratio of 30:1 to make pH of the solution be 11, heating and stirring at 40deg.C for 90min, centrifuging at 4000rpm for 20min, and retaining supernatant;
2) Adding hydrochloric acid as an acidic regulator into the supernatant to enable the pH of the solution to be 4.5, standing and precipitating for 60min, centrifuging at 4000rpm for 20min to obtain a precipitate, and freeze-drying the precipitate at-23 ℃ for 72h to obtain sea buckthorn protein, wherein the protein content in the sea buckthorn protein is measured to be 47.3%;
3) Dissolving sea buckthorn protein in deionized water according to a feed liquid ratio of 1:35, adding alkaline protease with substrate sea buckthorn protein content of 0.5% and chitosan with substrate sea buckthorn protein content of 2.5%, heating and stirring at 50 ℃ for enzymolysis for 4 hours, centrifuging at 4000rpm for 20min after enzymolysis is finished to obtain polypeptide liquid containing high-activity alpha-glucosidase inhibitory peptide, and detecting the inhibitory effect of the polypeptide liquid on alpha-glucosidase;
4) Concentrating, freezing and drying the polypeptide liquid to obtain the high-activity alpha-glucosidase inhibitory peptide.
The inhibition rate of alpha-glucosidase in the polypeptide liquid obtained in the step 3) of the present example was measured to be 80.4%.
The protein content in the sea buckthorn proteins obtained in the above examples and comparative examples and the inhibitory effect of the polypeptide liquid on α -glucosidase were compared, and the results are shown in table 1.
TABLE 1
From table 1, the invention can effectively improve the extraction rate of protein by selecting proper acid regulator, thus the subsequent polypeptide liquid has higher inhibition rate to alpha-glucosidase, and the invention can effectively promote the aggregation and precipitation of sea buckthorn protein by taking acetic acid as the acid regulator, thus the extraction rate of protein is higher.
When chitosan and alkaline protease are used for enzymolysis together, the chitosan has higher cationic property as an amino sugar compound, on one hand, the solution alkaline environment can be endowed in the enzymolysis liquid, the catalytic activity of the alkaline protease is improved, and on the other hand, the solubility and stability of the sea buckthorn protein can be promoted, so that the enzymolysis efficiency is improved, and the enzymolysis product has higher alpha-glucosidase inhibition activity.
Comparative example 3
The comparative example was different from example 1 in that pepsin was substituted for alkaline protease, and the remaining process steps were the same as example 1, to obtain a polypeptide liquid of the comparative example.
Comparative example 4
The comparative example is different from comparative example 3 in that no enzymolysis auxiliary agent is added, and the parameters of the other process steps are the same as those of comparative example 3, so that the polypeptide liquid of the comparative example is obtained.
Comparative example 5
The comparative example differs from example 1 in that the alkaline protease was replaced with papain, and the remaining process steps were the same as in example 1, resulting in a polypeptide solution of the comparative example.
Comparative example 6
The comparative example is different from comparative example 5 in that no enzymolysis auxiliary agent is added, and the other process steps are the same as those of comparative example 5, so as to obtain the polypeptide liquid of the comparative example.
The inhibition rate of the polypeptide liquid to the alpha-glucosidase is prepared under different enzymolysis conditions of comparative example 1 and the above comparative example, and the results are shown in table 2.
TABLE 2
As can be seen from Table 2, only when the enzymolysis system is alkaline protease and chitosan, the enzymolysis effect is obviously promoted, and the enzymolysis system of chitosan and pepsin is selected, so that the enzymolysis effect is inhibited.
Example 3
This example was conducted to investigate the effect of the polypeptide liquid produced at different alkaline protease addition amounts on the inhibition effect of α -glucosidase, and the results of adjusting the addition amounts of alkaline protease in step 3) to 0.1%, 0.3%, 0.5%, 1%, 1.5%, and the other preparation process parameters were the same as in example 1, to produce polypeptide liquid at different alkaline protease addition amounts, and comparing the α -glucosidase inhibition activities thereof, and the results are shown in table 3.
TABLE 3 Table 3
As can be seen from Table 2, the addition amount of alkaline protease has a significant effect on the alpha-glucosidase inhibitory activity of the polypeptide liquid, when the protease content is too low, the digestion of sea buckthorn protein is incomplete, the yield of inhibitory peptide is reduced, the inhibitory effect of the polypeptide liquid is poor, and the excessive content may cause excessive enzymolysis, so that the inhibitory peptide is degraded or converted into other products or is enzymatically decomposed into smaller peptide fragments, and the inhibition rate of the alpha-glucosidase is reduced instead.
Example 4
The present example was used to investigate the effect of the polypeptide liquid prepared at different chitosan addition amounts on the inhibition effect of α -glucosidase, and the preparation process parameters of the other preparation process parameters were the same as those of example 1 except that the chitosan addition amounts in step 3) were adjusted to 1%, 2.5%, 5%, 7.5%, and 10%, respectively, to prepare polypeptide liquids at different alkaline protease addition amounts, and the results of comparison of the α -glucosidase inhibition activities are shown in table 4.
TABLE 4 Table 4
From table 4, it can be seen that the addition amount of chitosan has a significant effect on the α -glucosidase inhibitory activity of the polypeptide liquid, and when the chitosan content is too low, the protein dissolution cannot be effectively promoted to increase the protease activity, and when the chitosan content is too high, the viscosity of the reaction liquid is increased, the enzymolysis reaction rate is reduced, and the generation of active peptide is inhibited, so that the addition amount of chitosan as an auxiliary enzymolysis agent needs to be strictly controlled.
Example 5
The present example was used to investigate the effect of different types of enzymolysis aids on the inhibition effect of the prepared polypeptide liquid on α -glucosidase, and the preparation process parameters of the preparation of the chitosan in step 3) were the same as those of example 1 except that the chitosan was polyethylene glycol, urea, ammonium sulfate and ethylene glycol, so as to prepare polypeptide liquids with different alkaline protease addition amounts, and the results of comparing the α -glucosidase inhibition activities are shown in table 5.
As can be seen from Table 5, the different types of enzymolysis auxiliary agents have important influence on the alpha-glucosidase inhibition rate of the product, compared with other auxiliary agents, the special structure of chitosan can interact with or the active center of the enzyme to improve the enzyme activity and stability, and promote the dissolution of sea buckthorn proteins, urea and ammonium sulfate have reverse influence on enzymolysis, and glycol and polyethylene glycol can also promote the enzymolysis effect to a certain extent, but are far less than chitosan.
In summary, the invention provides a method for preparing alpha-glucosidase inhibitory peptide from sea buckthorn, which firstly optimizes the extraction scheme of sea buckthorn protein to obviously improve the protein extraction rate, secondly optimizes the enzymolysis system, introduces chitosan as an enzymolysis auxiliary agent to promote enzymolysis, improves the enzyme activity and stability, simultaneously gives consideration to improving the solubility of sea buckthorn protein, realizes the obvious improvement of the alpha-glucosidase inhibitory effect of polypeptide liquid under the combined action, and has important significance for recycling sea buckthorn.
It should be noted that the above embodiments are only for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solution of the present invention may be modified or substituted without departing from the spirit and scope of the technical solution of the present invention, which is intended to be covered in the scope of the claims of the present invention.
Claims (10)
1. A preparation method of a sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide is characterized by comprising the following steps: comprising the steps of (a) a step of,
dissolving sea buckthorn powder into alkaline solution to reach pH of 10-12, heating and stirring, centrifuging and maintaining supernatant;
adding an acidic regulator into the supernatant to enable the pH value of the solution to be 4-5, standing, precipitating, centrifuging to obtain a precipitate, and freeze-drying the precipitate to obtain the sea buckthorn protein;
dissolving sea buckthorn protein in deionized water, adding protease and enzymolysis auxiliary agent, heating and stirring for enzymolysis, centrifuging after enzymolysis is completed to obtain polypeptide liquid containing high-activity alpha-glucosidase inhibitory peptide, concentrating the polypeptide liquid, freezing and drying to obtain the high-activity alpha-glucosidase inhibitory peptide.
2. The method for preparing the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide according to claim 1, wherein the method comprises the following steps: the alkaline solution comprises one of sodium hydroxide solution, potassium hydroxide solution or sodium bicarbonate solution.
3. The method for preparing the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide according to claim 1, wherein the method comprises the following steps: the acidity regulator comprises one of hydrochloric acid, sulfuric acid or acetic acid.
4. The method for preparing the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide according to claim 1, wherein the method comprises the following steps: the feed liquid ratio of the sea buckthorn protein to the deionized water is 1:20-50.
5. The method for preparing the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide according to claim 1, wherein the method comprises the following steps: the protease comprises one or more of alkaline protease, papain or pepsin.
6. The method for preparing the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide according to claim 5, wherein the method comprises the following steps: the addition amount of the protease is 0.1% -1% of the substrate sea buckthorn protein.
7. The method for preparing the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide according to claim 1, wherein the method comprises the following steps: the enzymolysis auxiliary agent comprises one or more of chitosan, polyethylene glycol, amine sulfate or ethylene glycol.
8. The method for preparing the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide according to claim 7, wherein the method comprises the following steps: the addition amount of the enzymolysis auxiliary agent is 1-5% of the substrate sea buckthorn protein.
9. The method for preparing the sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide according to claim 1, wherein the method comprises the following steps: the enzymolysis time is 2-6 h.
10. Use of a highly active α -glucosidase inhibitory peptide prepared by the preparation method according to any one of claims 1 to 9 for the preparation of a product for the treatment or prevention of hyperglycemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311192951.9A CN117265051A (en) | 2023-09-15 | 2023-09-15 | Sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311192951.9A CN117265051A (en) | 2023-09-15 | 2023-09-15 | Sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117265051A true CN117265051A (en) | 2023-12-22 |
Family
ID=89215221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311192951.9A Pending CN117265051A (en) | 2023-09-15 | 2023-09-15 | Sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117265051A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117837707A (en) * | 2024-01-11 | 2024-04-09 | 广州好孝心营养健康研究有限公司 | Solid beverage and preparation method and application thereof |
-
2023
- 2023-09-15 CN CN202311192951.9A patent/CN117265051A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117837707A (en) * | 2024-01-11 | 2024-04-09 | 广州好孝心营养健康研究有限公司 | Solid beverage and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN117265051A (en) | Sea buckthorn-based high-activity alpha-glucosidase inhibitory peptide and preparation method and application thereof | |
| CN105360853A (en) | Preparation method of passion fruit-tomato fermented beverage | |
| CN1364873A (en) | Process for brewing organge fruit vinegar | |
| CN101536803A (en) | Method for preparing buckwheat rutin drinks | |
| Fan et al. | Nutritional composition and α-glucosidase inhibitory activity of five Chinese vinegars | |
| CN108523112B (en) | Silkworm chrysalis food base material and preparation method and application thereof | |
| CN104188015A (en) | Female health beverage prepared from tea flower and maca powder | |
| CN104055119B (en) | A kind of female health lozenge prepared by Tea Flower and pueraria root powder | |
| CN112725398B (en) | Pea peptide with auxiliary hypoglycemic function and preparation method thereof | |
| CN102835709A (en) | Beauty beverage containing collagen | |
| CN101955874B (en) | Method for brewing bitter almond liqueur | |
| CN107896921B (en) | Tremella biotransformation composition of maca and dioscorea opposita and preparation method thereof | |
| CN1476782A (en) | Preparation process of complete-component pearl product | |
| CN109393490A (en) | The chromium-rich nutritious spirulina powder and preparation method of the extract containing natural flavone | |
| CN1276723C (en) | Water soluble royal jelly and its dry powder and method for preparing them | |
| CN106636278A (en) | Preparation technology of antioxidant peptide of jujubes | |
| CN1189104C (en) | Production process of health glossy ganoderma food | |
| CN109938068B (en) | Method for reducing middle-advanced glycosylation end products of cookies | |
| CN102754872A (en) | Concentrated yacon juice and preparation process thereof | |
| CN111758870A (en) | Instant chaenomeles speciosa solid beverage and preparation method thereof | |
| CN110692718A (en) | Gastrodia elata health-care yoghourt and preparation method thereof | |
| CN109393489A (en) | Selenium enriched Spirulina powder and preparation method thereof | |
| CN109077206A (en) | A kind of pumpkin raspberry composite fruit juice formula and its processing technology | |
| CN115191489B (en) | Preparation method of gastrodia elata protein emulsion | |
| CN109329593A (en) | The chromium-rich spirulina enzymolysis slag mixed feed of selenium-rich and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |